Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin ...

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at At MaxCyte ®, we are committed to building better cells together. As a leading ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised ...

A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-National Institute of High Security Animal Diseases (NIHSAD), Bhopal, ...

VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced ...

IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2025, and ...

A live audio webcast of the TD Cowen and Barclays Conference presentations can also be accessed on the Events & Presentations section of the Supernus Pharmaceuticals website at www.supernus.com.

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events ...

“At MacroGenics, our top priority is patient safety,” said Eric Risser, President and CEO. “MacroGenics is fully committed to working closely with the FDA to resolve the partial clinical hold and we ...

Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board ...

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will ...